Cholangiocarcinoma (CCA) represents a disease entity that comprises a heterogeneous group of biliary malignant neoplasms, with variable clinical presentation and severity. It may be classified according to its anatomical location and distinguished in intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA), each subtype implying distinct epidemiology, biology, prognosis, and strategy for clinical management. Its incidence has increased globally over the past few decades, and its mortality rate remains high due to both its biological aggressiveness and resistance to medical therapy. Surgery is the only potentially curative treatment and is the standard approach for resectable CCA; however, more than half of the patients have locally advanced or metastatic disease at presentation. For patients with unresectable CCA, the available systemic therapies are of limited effectiveness. However, the advances of the comprehension of the complex molecular landscape of CCA and its tumor microenvironment could provide new keys to better understand the pathogenesis, the mechanisms of resistance and ultimately to identify promising new therapeutic targets. Recently, clinical trials targeting isocitrate dehydrogenase (IDH)-1 mutations and fibroblast growth factor receptor (FGFR)-2 fusions, as well as immunotherapy showed promising results. All these new and emerging therapeutic options are herein discussed.

Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R., Bidoli, P., et al. (2020). New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. CELLS, 9(3) [10.3390/cells9030688].

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma

Massironi, Sara
Primo
;
Bidoli, Paolo;Invernizzi, Pietro
Ultimo
2020

Abstract

Cholangiocarcinoma (CCA) represents a disease entity that comprises a heterogeneous group of biliary malignant neoplasms, with variable clinical presentation and severity. It may be classified according to its anatomical location and distinguished in intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA), each subtype implying distinct epidemiology, biology, prognosis, and strategy for clinical management. Its incidence has increased globally over the past few decades, and its mortality rate remains high due to both its biological aggressiveness and resistance to medical therapy. Surgery is the only potentially curative treatment and is the standard approach for resectable CCA; however, more than half of the patients have locally advanced or metastatic disease at presentation. For patients with unresectable CCA, the available systemic therapies are of limited effectiveness. However, the advances of the comprehension of the complex molecular landscape of CCA and its tumor microenvironment could provide new keys to better understand the pathogenesis, the mechanisms of resistance and ultimately to identify promising new therapeutic targets. Recently, clinical trials targeting isocitrate dehydrogenase (IDH)-1 mutations and fibroblast growth factor receptor (FGFR)-2 fusions, as well as immunotherapy showed promising results. All these new and emerging therapeutic options are herein discussed.
Articolo in rivista - Review Essay
chemotherapy; cholaniocarcinoma; immunotherapy; molecular landscape; targeted-therapy
English
11-mar-2020
2020
9
3
688
open
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R., Bidoli, P., et al. (2020). New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. CELLS, 9(3) [10.3390/cells9030688].
File in questo prodotto:
File Dimensione Formato  
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 2.14 MB
Formato Adobe PDF
2.14 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/268015
Citazioni
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 54
Social impact